Amgen Inc has signed a research agreement with two Milan-based institutions to develop an ex-vivo gene therapy for cancer. The research will be based on some of the same principles that guided the development of Strimvelis, an ex vivo stem cell gene therapy that was approved by the European Commission in May of this year.
